Serum IL-33 level is a predictor of progression-free survival after chemotherapy
Metrics: PDF 1613 views | HTML 1358 views | ?
Wenwei Hu1,2,3,*, Chen Wu1,2,3,*, Xiaodong Li1,2,3,*, Zhuojun Zheng2, Quanqin Xie2, Xu Deng2, Jingting Jiang2,3 and Changping Wu1
1Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China
2Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China
3Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu Province, China
*These authors should be considered as co-first authors
Changping Wu, email: email@example.com
Jingting Jiang, email: firstname.lastname@example.org
Keywords: IL-33, gastric cancer, chemotherapy, decline extent, progression-free survival
Received: February 03, 2017 Accepted: March 02, 2017 Published: March 28, 2017
This study aimed to evaluate the association between of serum IL-33 (sIL-33) level in gastric cancer (GC) patients and progression-free survival (PFS). A total of 62 patients with advanced GC and 32 healthy subjects were enrolled. sIL-33 level was detected in pre-chemotherapy patients, post-chemotherapy patients and healthy subjects, respectively. sIL-33 levels were 131.9 (95% CI 105.9-184.9) pg/mL, 95.1 (95% CI 70.8-140.2) pg/mL and 95.7 (95% CI 73.3-114.3) pg/mL in pre-chemotherapy patients, post-chemotherapy patients and controls, respectively. The sIL-33 level in pre-chemotherapy patients was significantly higher than that in both post-chemotherapy patients and controls (P < 0.001 and P < 0.001, respectively). There was no statistically significant difference between the sIL-33 levels in post-chemotherapy patients and controls (P > 0.05). PFS in patients with the decline extent > 30.1% (median PFS not reached) was statistically significant longer than that (median PFS 7 months, 95% CI 1.569 - 12.431) in patients with the decline extent ≤ 30.1% (P = 0.003). The decline extent of sIL-33 level (> 30.1%) was associated with longer PFS (P = 0.006). Distant metastasis was associated with the decline extent of sIL-33 level (P = 0.034). The decline extent of sIL-33 after chemoresistance could be regarded as a predictor of the PFS of GC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.